A scientific round table discussion titled “Prediction and Prevention of Spontaneous Preterm Birth” was successfully conducted in Sulaymaniyah on January 29, 2026, organized by Laboratorio ELEA and attended by a group of gynecologists from the region.
The session focused on the clinical role of ProGest® (micronized progesterone) in obstetric and reproductive practice, providing evidence-based guidance on appropriate dosing, treatment duration, and patient selection. The discussion addressed key clinical indications, including threatened miscarriage, luteal phase support in IVF/ART cycles, and prevention of preterm birth in high-risk pregnancies.
Special emphasis was placed on optimizing maternal and fetal outcomes while ensuring safe and rational use of progesterone therapy in daily clinical practice. The round table format encouraged active participation, enabling attendees to engage in focused scientific dialogue and exchange real-world clinical experiences.
The event concluded with individual, scientific follow-up discussions, providing deeper clarification of clinical scenarios and reinforcing engagement with participating gynecologists.
Through such targeted educational activities, XenoFarma and its partners continue to support evidence-driven obstetric care, professional knowledge exchange, and improved clinical outcomes in maternal health.
Event Date: January 29, 2026
Start Time: 12:00 PM
Venue: Titanic Hotel
City: Sulaymaniyah, Iraq
